GenScript Granted Higher MSCI Sustainability Review Grade ('AA')
GenScript Biotech Corporation Achieves AA MSCI ESG Rating, Recognizing Sustainability Leadership
GenScript Biotech Corporation, one of the world's largest biotech companies, has been upgraded to an AA ESG rating by MSCI, a leading global index provider [1]. This prestigious rating places GenScript among the global leaders in sustainability, reflecting its commitment to environmental, social, and governance (ESG) practices [5].
The upgrade is a testament to GenScript's excellence in various areas, including product safety and quality, human capital development, environmental practices, and governance [5]. The company's strong ESG performance enhances its operational resilience and creates long-term value for investors and stakeholders worldwide.
GenScript's environmental leadership is evident in its carbon reduction targets, which have been validated by the Science Based Targets initiative (SBTi). This validation demonstrates GenScript's strong commitment and actions toward combating climate change, aligning with the Paris Agreement's goal to limit global warming to 1.5°C [1][2][3].
The company has also achieved a Silver Medal from EcoVadis, ranking in the top 15% globally for sustainability and top 10% within pharmaceutical manufacturing [1][2][3]. It has earned a "Low Risk" ESG rating from Morningstar Sustainalytics, further solidifying its position as a responsible and sustainable biotech company [1][2][3][4].
GenScript's commitment to sustainability extends beyond its own operations. The company is a participant in the United Nations Global Compact (UNGC), adhering to its ten universal principles on human rights, labor, environment, and anti-corruption [1][2]. It is also a supplier partner of the Pharmaceutical Supply Chain Initiative (PSCI), which promotes sustainable value chains within the pharmaceutical industry [1][2].
The inclusion of GenScript in the FTSE4Good Index Series, a global benchmark recognizing strong ESG practices, further underscores the company's commitment to sustainability [1][2][3]. GenScript emphasizes integrating sustainability into its global business strategy, aiming to lead the life sciences toward a greener, responsible future through innovation and collaboration [2][3].
Sherry Shao, Rotating CEO of GenScript Biotech, stated that the AA rating is a testament to their ESG performance. "We are committed to making people and nature healthier through biotechnology, and this rating underscores our dedication to sustainability," she said [5].
GenScript plans to continue pushing boundaries and driving sustainable growth in the biotech industry, aligning with its mission to 'Make People and Nature Healthier through Biotechnology'. The company's AA MSCI ESG rating is a significant milestone in its journey towards a more sustainable future.
[1] GenScript Biotech Corporation Press Release, 2022. [2] GenScript Biotech Corporation Sustainability Report, 2021. [3] Science Based Targets initiative, 2022. [4] Morningstar Sustainalytics, 2022. [5] EcoVadis, 2022.
- GenScript Biotech Corporation's AA MSCI ESG rating, a recognition of its commitment to sustainability, indicates its dedication towards incorporating science and technology, particularly in its environmental practices and carbon reduction targets.
- The company's strong ESG performance is not only a depiction of its operational resilience and long-term value creation for investors and stakeholders but also a bold statement of its commitment to the advancement of science and technology for a greener, more sustainable future.
){kind=link}